NCT04471727: An ongoing trial by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
This trial is ongoing. It must report results 2 years, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04471727 |
|---|---|
| Title | A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3). |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 14, 2020 |
| Completion date | Jan. 28, 2028 |
| Required reporting date | Jan. 27, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 22, 2026 |
| Days late | None |